Welcome to our dedicated page for Park Ha Biological Technology Co., Ltd. SEC filings (Ticker: BYAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Park Ha Biological Technology Co., Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Park Ha Biological Technology Co., Ltd.'s regulatory disclosures and financial reporting.
Park Ha Biological Technology Co., Ltd. is offering 21,875,000 Units, each with one Class A Ordinary Share and one Warrant, and registering 196,875,000 Class A Ordinary Shares issuable upon Warrant exercise. The public offering price is $0.112 per Unit, for a maximum gross proceed of $2,450,000 on a best-efforts basis.
Each Warrant initially allows purchase of one Class A Ordinary Share at $0.112 for one year, but also includes a zero exercise price option under which holders may receive nine Class A Ordinary Shares per Warrant for no additional consideration, up to 196,875,000 shares in total. The company expects no meaningful cash proceeds from Warrant exercises and plans to use estimated net offering proceeds of about $2.142 million mainly to expand directly operated stores.
Class A Ordinary Shares trade on Nasdaq as “BYAH.” The company operates skincare product development and franchised stores in China through PRC subsidiaries, with revenues primarily from product sales and franchise fees, and highlights extensive regulatory, structural, and PRC-related legal and cash-transfer risks, as well as dual-class voting control concentrated with its founder.
Park Ha Biological Technology Co., Ltd. filed Amendment No. 3 to its Form F-1 registration statement to update certain exhibits and restate the exhibit index, while leaving the previously filed prospectus unchanged.
The filing describes Cayman Islands–style indemnification for directors and officers, subject to limits under Cayman law and U.S. Securities Act public policy, and confirms standard SEC undertakings related to post-effective amendments and offering liability.
It also reviews recent unregistered securities activity, including 5,000,000 Ordinary Shares issued on October 11, 2022 at incorporation, a June 29, 2024 forward split, a December 2024 IPO of 1,200,000 Ordinary Shares at $4.00 per share plus a 174,403-share over-allotment, and share issuances of 3,000,000 and 4,500,000 Ordinary Shares under the 2025 and Amended and Restated 2025 Share Incentive Plans, contributing to 33,874,403 Ordinary Shares issued and outstanding out of 2,500,000,000 authorized as of the prospectus date.